Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sage Therapeutics, Inc.    SAGE

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Sage Therapeutics : Announces Chief Executive Jeff Jonas to Undergo Scheduled Medical Procedure

10/22/2020 | 06:32am EST

Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that Jeff Jonas, M.D., chief executive officer, will undergo a scheduled surgical procedure today. The Company anticipates he will make a full recovery and return to his role full-time in December 2020. While Dr. Jonas is recuperating, he will be available as needed, and during this time, the Sage leadership team will direct business operations. In addition, Sage’s experienced Board of Directors will continue to serve as a resource.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.


© Business Wire 2020
All news about SAGE THERAPEUTICS, INC.
07:24aSAGE THERAPEUTICS : Wedbush Adjusts Price Target on Sage Therapeutics to $98 Fro..
MT
01/07SAGE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other E..
AQ
01/07SAGE THERAPEUTICS : Provides 2021 Corporate Strategy Update at J.P. Morgan Healt..
BU
01/04SAGE THERAPEUTICS : Guggenheim Upgrades Sage Therapeutics to Buy From Neutral, S..
MT
01/04SAGE THERAPEUTICS : RBC Downgrades Sage Therapeutics to Sector Perform From Outp..
MT
2020SAGE THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
2020SAGE THERAPEUTICS : to Present at the 39th Annual J.P. Morgan Healthcare Confere..
BU
2020SAGE THERAPEUTICS : Names Barry Greene CEO
MT
2020SAGE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2020SAGE THERAPEUTICS : Announces the Appointment of Barry Greene as CEO
BU
More news
Financials (USD)
Sales 2020 7,04 M - -
Net income 2020 -473 M - -
Net cash 2020 1 245 M - -
P/E ratio 2020 -10,1x
Yield 2020 -
Capitalization 5 326 M 5 326 M -
EV / Sales 2020 579x
EV / Sales 2021 15,1x
Nbr of Employees 675
Free-Float 87,7%
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 96,90 $
Last Close Price 91,38 $
Spread / Highest target 107%
Spread / Average Target 6,04%
Spread / Lowest Target -34,3%
EPS Revisions
Managers and Directors
NameTitle
Barry E. Greene President, Chief Executive Officer & Director
Kevin Paul Starr Chairman
Michael Cloonan Chief Operating Officer
Kimi E. Iguchi Chief Financial Officer & Treasurer
Albert J. Robichaud Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
SAGE THERAPEUTICS, INC.5.63%5 326
MODERNA, INC.24.10%51 304
LONZA GROUP AG2.46%48 618
CELLTRION, INC.-12.53%38 786
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601